The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival

Transplantation

Volumn 82, Issue 11, 2006, Pages 1441-1448

  Heinze, Georg ^a   Collins, Sean ^b   Benedict, Michael A ^b   Nguyen, Louis L ^c   Kramar, Reinhard ^d   Winkelmayer, Wolfgang C ^c   Haas, Martin ^a   Kainz, Alexander ^a,e   Oberbauer, Rainer ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Hospital of Wels   (Austria)

^e Hospital Wels ^*  (Austria)

Author keywords

ACEI ARB; ARF; Graft survival; Kidney; Patient survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CADAVER KIDNEY; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HAZARD ASSESSMENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTISCHEMIC ACUTE TRANSPLANT FAILURE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DELAYED GRAFT FUNCTION; FEMALE; GRAFT SURVIVAL; HUMANS; ISCHEMIA; KIDNEY; KIDNEY TRANSPLANTATION; MALE;

EID: 33845699313     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000244587.74768.f7     Document Type: Article

References (24)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
2. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
3. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861.
6. Inigo P, Campistol JM, Saracho R, et al. Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract 2003; 95: c84.
7. Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Horl WH, Haas M. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004; 43: 1065.
8. Heinze G, Mitterbauer C, Regele HM, et al. Angiotensin-converting enzyme inhibitor or AT1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
9. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.
10. Snapinn SM, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. American Statistician 2005; 59: 301.
11. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc B 1972; 34: 187.
12. D'Agostino R, Rubin D. Estimating and using propensity scores with partially missing data. J Am Stat Assoc 2000; 95: 749.
13. Hosmer D, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data., New York: John Wiley and Sons; 1999.
14. Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003; 16: 313.
15. Mas VR, Alvarellos T, Maluf DG, et al. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy. Transpl Int 2004; 17: 540.
16. Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003; 76: 1170.
17. Haas M, Leko-Mohr Z, Erler C, Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002; 40: 458.
18. Artz MA, Hilbrands LB, Borm G, Assmann KJ, Wetzels JF. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2852.
19. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
20. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
21. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194.
22. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362.
23. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002; 40: 1255.
24. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570.